Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
Business Wire•23/10/2026•19:20 ET
6
Key Highlights
- ➤FILSPARI cut sCD163 60.1% versus irbesartan’s 26.0% at Week 110
- ➤FILSPARI reduced urinary MCP-1 49.9% versus irbesartan’s 10.7% at Week 110
- ➤FILSPARI lowered urinary E-selectin 38.9% versus irbesartan’s 7.8% at Week 110
- ➤FILSPARI reduced urinary KIM-1 35.2% versus irbesartan’s 8.1% at Week 110
- ➤Biomarker analysis included 295 of 404 PROTECT Study participants
Expert Statements
Jula Inrig, Chief medical officer of Travere Therapeutics
“These biomarker data provide new insight into how FILSPARI’s dual mechanism of action may modify the underlying biology of IgA nephropathy. When considered alongside the PROTECT results which demonstrated superior proteinuria reduction and a slower rate of kidney function decline compared with maximum labeled dose irbesartan, as well as published real-world evidence showing consistent outcomes in clinical practice, the totality of evidence supports the use of FILSPARI as a non-immunosuppressive, kidney-targeted, foundational first-line treatment for IgA nephropathy.”
Chee Kay Cheung, Consultant nephrologist at University Hospitals of Leicester NHS Trust
“These findings extend the exploratory signal observed in SPARTAN and show in a larger, randomized study that dual endothelin and angiotensin receptor antagonism may modulate several biological pathways associated with IgAN pathophysiology.”
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI(®) (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
FILSPARI achieved greater reductions in biomarkers linked to kidney inflammation and injury than maximum labeled dose irbesartan
Get started
Create a free account to read the full story.